Coumestrol

Coumestrol at a Glance

Coumestrol is the best-known coumestan — a small class of plant compounds built from a coumarin ring fused to a benzofuran, the two sharing a carbon–carbon double bond ^{2Reference 2Tu Y et al. · 2021Naturally occurring coumestans from plants, their biological activities and therapeutic effects on human diseasesView study →}. That fused structure matters for how the page is read: coumestrol is not a simple coumarin (like coumarin or scopoletin) and not a furanocoumarin (like bergapten or imperatorin). It sits in its own structural family, and — unlike the furanocoumarins — it is not phototoxic.

What makes coumestrol notable is endocrine, not photochemical. It is one of the most potent dietary phytoestrogens, binding estrogen receptors directly and acting as an estrogen-receptor agonist with a marked preference for estrogen receptor beta (ERβ) over ERα ^{3Reference 3Park S et al. · 2023AnimalProtective effects of coumestrol on metabolic dysfunction and its estrogen receptor-mediated action in ovariectomized miceView study →}. That single property drives most of the interest in it: the menopausal, bone and metabolic effects studied in animals, the reason clover and alfalfa are looked at for hormonal support, and the important caveat that estrogenic activity cuts both ways in hormone-sensitive tissues.

Most of the human-relevant evidence is laboratory and animal work, plus population data on dietary phytoestrogens as a group. There is no established clinical use of isolated coumestrol.

A Potent Coumestan Phytoestrogen

Coumestrol’s defining feature is that its phenolic ring system is close enough in shape and spacing to 17β-estradiol to occupy the estrogen-receptor binding pocket. It behaves as an estrogen-receptor agonist, and — the point that recurs across the biology — it binds ERβ more tightly than ERα ^{3Reference 3Park S et al. · 2023AnimalProtective effects of coumestrol on metabolic dysfunction and its estrogen receptor-mediated action in ovariectomized miceView study →}. ERβ predominates in bone, brain, vasculature and parts of the immune system, which is why coumestrol’s studied effects cluster in exactly those tissues rather than reproducing the full uterine/breast profile of estradiol.

Its potency, relative to other dietary phytoestrogens, is high: coumestans and coumestrol are consistently ranked among the stronger estrogen-receptor binders in the phytoestrogen literature, well above the trace native isoflavones daidzein and genistein on a molar basis, though present in food at much lower amounts ^{1,2Reference 1Reinli K · 1996Phytoestrogen content of foods — a compendium of literature valuesView study →Reference 2Tu Y et al. · 2021Naturally occurring coumestans from plants, their biological activities and therapeutic effects on human diseasesView study →}. In an ovariectomised-mouse model, coumestrol acted as a potent ER agonist and its metabolic benefits were abolished by an ERβ-selective antagonist but not an ERα-selective one — direct evidence that the ERβ route carries its effects ^{3Reference 3Park S et al. · 2023AnimalProtective effects of coumestrol on metabolic dysfunction and its estrogen receptor-mediated action in ovariectomized miceView study →}.

The double-edged consequence is unavoidable and belongs up front: a molecule that activates estrogen receptors can be supportive in a low-estrogen (postmenopausal) setting and unwanted in an estrogen-driven one. The Toxicity & Safety section returns to this.

What It's Used For

The evidence is dominated by cell and animal work on the isolated molecule, with human relevance coming mainly from dietary-phytoestrogen epidemiology in which coumestrol is one contributor among several. Read the per-row basis below — the estrogenic mechanism is well characterised, but clinical outcomes for coumestrol specifically are not established.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Scores here reflect mostly preclinical data on the isolate plus group-level dietary epidemiology, so read each row’s basis.

01Menopausal / Estrogenic SupportShaky42%ERβ-dependent effects in ovariectomised mice + phytoestrogen mechanism ^{3Reference 3Park S et al. · 2023AnimalProtective effects of coumestrol on metabolic dysfunction and its estrogen receptor-mediated action in ovariectomized miceView study →}

02Bone HealthShaky38%Osteoblast proliferation/differentiation in vitro & animal cells ^{6Reference 6Wu XT et al. · 2009AnimalCoumestrol promotes proliferation and osteoblastic differentiation in rat bone marrow stromal cellsView study →}

03Neuroprotection & CognitionShaky34%Cerebral-ischaemia and memory models; MAO-A / amyloid mechanisms ^{7,8Reference 7Castro CC et al. · 2022Coumestrol pre-treatment improves spatial learning and memory deficits following transient cerebral ischemia recruiting hippocampal GluR2 AMPA receptorsView study →Reference 8Seong SH et al. · 2022Phytoestrogen coumestrol selectively inhibits monoamine oxidase-A and amyloid β self-aggregationView study →}

04Metabolic & Anti-ObesityShaky30%OVX-mouse fat/insulin + steatotic-hepatocyte models ^{3,10Reference 3Park S et al. · 2023AnimalProtective effects of coumestrol on metabolic dysfunction and its estrogen receptor-mediated action in ovariectomized miceView study →Reference 10Bzdęga W et al. · 2023AnimalCoumestrol as a new substance that may diminish lipid precursors of the inflammation in steatotic primary rat hepatocytesView study →}

05Antioxidant / Anti-InflammatoryShaky24%In-vitro antioxidant activity as a coumestan; lipid/inflammation markers ^{2,10Reference 2Tu Y et al. · 2021Naturally occurring coumestans from plants, their biological activities and therapeutic effects on human diseasesView study →Reference 10Bzdęga W et al. · 2023AnimalCoumestrol as a new substance that may diminish lipid precursors of the inflammation in steatotic primary rat hepatocytesView study →}

Mechanisms

The load-bearing target is ERβ: its tissue distribution (bone, brain, vasculature, metabolic tissue) predicts where coumestrol’s studied effects land, and the ERβ-antagonist-reversal experiment ^{3Reference 3Park S et al. · 2023AnimalProtective effects of coumestrol on metabolic dysfunction and its estrogen receptor-mediated action in ovariectomized miceView study →} ties the metabolic benefit directly to that receptor.

Pharmacokinetics

Human pharmacokinetic data for coumestrol are sparse. As a small, moderately lipophilic diphenolic it is absorbed orally, undergoes phase-II conjugation (glucuronidation/sulfation) typical of dietary polyphenols, and circulates largely as conjugates — so systemic exposure to the free aglycone is likely modest, a caveat for in-vitro potencies measured on the free molecule. Dietary intake itself is low, because even the richest foods carry it at microgram-per-gram levels ^{4Reference 4Ohta T et al. · 2021Effective methods for increasing coumestrol in soybean sproutsView study →}, so ordinary diets deliver far less than the doses used in animal studies (~5–10 mg/kg) ^{3Reference 3Park S et al. · 2023AnimalProtective effects of coumestrol on metabolic dysfunction and its estrogen receptor-mediated action in ovariectomized miceView study →}. A dedicated absorption/half-life dataset for isolated coumestrol in humans has not been characterised here.

Clinical Trials

There are no clinical trials of isolated coumestrol. Human evidence is limited to dietary-phytoestrogen epidemiology, in which coumestrol is one of several intake variables — for example a 2026 prospective analysis of the PLCO cohort examined dietary phytoestrogen intake against receptor-defined breast-cancer subtypes ^{9Reference 9Reger MK et al. · 2026ObservationalDietary phytoestrogen intake and risk of receptor-defined breast cancer subtypes: a prospective analysis of the PLCO Cancer Screening Trial cohortView study →}. All mechanistic and outcome work on the molecule itself is preclinical.

Last checked: July 2026.

Isolate vs. Plant Studies

The mechanistic and animal work reviewed above is almost entirely on isolated, synthetic-grade coumestrol — a strength for attributing effects to the molecule (the ERβ-antagonist-reversal experiment ^{3Reference 3Park S et al. · 2023AnimalProtective effects of coumestrol on metabolic dysfunction and its estrogen receptor-mediated action in ovariectomized miceView study →} is only possible with the pure compound), but a limit for translating to food or herb. In the whole-plant setting coumestrol never acts alone: in red clover and alfalfa it is a minor partner to the dominant methylated isoflavones formononetin and biochanin-a (which are demethylated in vivo to daidzein and genistein), so a clover extract’s estrogenic effect cannot be assigned to coumestrol ^{1Reference 1Reinli K · 1996Phytoestrogen content of foods — a compendium of literature valuesView study →}. Human trials of clover and soy products therefore test isoflavone-rich mixtures, not coumestrol. The one place the plant delivers coumestrol as a leading phytoestrogen is sprouts — where coumestan content rises sharply on germination ^{4Reference 4Ohta T et al. · 2021Effective methods for increasing coumestrol in soybean sproutsView study →}.

Its Role in Plants

Coumestans such as coumestrol are phytoalexins — defence compounds whose synthesis is induced by stress. Coumestrol accumulates in legumes in response to fungal infection, wounding and other stress, which is why germinating and infected tissue carries far more than the resting seed: sprouting soybeans and stressed alfalfa up-regulate the phenylpropanoid/isoflavonoid pathway that feeds coumestan biosynthesis ^{2,4Reference 2Tu Y et al. · 2021Naturally occurring coumestans from plants, their biological activities and therapeutic effects on human diseasesView study →Reference 4Ohta T et al. · 2021Effective methods for increasing coumestrol in soybean sproutsView study →}. The estrogenic activity that interests pharmacologists is, in the plant, incidental to a role in pathogen defence. This is plant biology and should not be read as human pharmacology.

Prevalence in Nature

Coumestrol is a minor but characteristic constituent of forage legumes and their sprouts. The classic dietary compendia rank the richest sources as alfalfa and clover sprouts, split peas, and other sprouted legumes, with mature soybean carrying little until it is germinated ^{1Reference 1Reinli K · 1996Phytoestrogen content of foods — a compendium of literature valuesView study →}. Quantified HPLC data confirm the sprouting effect: whole soybean sprouts contain about 1.76 µg/g fresh weight, concentrated in the hypocotyl (4.11 µg/g) rather than the cotyledons, and content is raised further by cultivation temperature ^{4Reference 4Ohta T et al. · 2021Effective methods for increasing coumestrol in soybean sproutsView study →}. It occurs at trace levels in a scatter of other foods (Brussels sprouts, spinach) and across many forage legumes ^{1Reference 1Reinli K · 1996Phytoestrogen content of foods — a compendium of literature valuesView study →}.

Because it is so stress- and germination-dependent, coumestrol content varies widely with plant part, maturity, infection status and processing — the same alfalfa or clover sample can differ several-fold, and the free molecule is usually a small fraction of a plant’s total phytoestrogen load, which is dominated by isoflavones ^{1,2Reference 1Reinli K · 1996Phytoestrogen content of foods — a compendium of literature valuesView study →Reference 2Tu Y et al. · 2021Naturally occurring coumestans from plants, their biological activities and therapeutic effects on human diseasesView study →}.

Major Natural Sources

Source	Part	Notes
Alfalfa (Medicago sativa)	sprouts, leaf	Classic richest source; the plant coumestrol was first isolated from 12Reference 12Bickoff EM et al. · 1964Isolation of coumestrol and other phenolics from alfalfa by countercurrent distributionView study →
Clover (Trifolium spp.)	sprouts, flowering tops	Minor partner to isoflavones formononetin/biochanin A 1Reference 1Reinli K · 1996Phytoestrogen content of foods — a compendium of literature valuesView study →
Split peas (Pisum sativum)	seed	Among the higher dietary sources in food compendia 1Reference 1Reinli K · 1996Phytoestrogen content of foods — a compendium of literature valuesView study →
Soybean (Glycine max)	sprouts (not mature bean)	~1.76 µg/g fresh; hypocotyl-concentrated 4Reference 4Ohta T et al. · 2021Effective methods for increasing coumestrol in soybean sproutsView study →

Discovery & Synthesis

Coumestrol was first isolated in 1957 from ladino clover and alfalfa by E. M. Bickoff and co-workers at the USDA, who were investigating the estrogenic activity of forage crops fed to livestock; the isolation from alfalfa and the structure — a hydroxylated coumestan — were confirmed by countercurrent distribution and correlated with estrogenic activity in the early 1960s ^{12Reference 12Bickoff EM et al. · 1964Isolation of coumestrol and other phenolics from alfalfa by countercurrent distributionView study →}. The name reflects the chemistry: a coumestan bearing hydroxyls at the 3- and 9-positions (3,9-dihydroxy-6H-benzofuro[3,2-c]chromen-6-one). It was, historically, the compound that put coumestans on the map as a phytoestrogen class distinct from the isoflavones ^{2Reference 2Tu Y et al. · 2021Naturally occurring coumestans from plants, their biological activities and therapeutic effects on human diseasesView study →}. Coumestrol used in research today is prepared by chemical synthesis or isolated from alfalfa/sprout material; it is not a large-scale commercial product.

Patents: not yet researched.

Toxicity & Safety

Coumestrol occurs in ordinary foods — sprouts, split peas, forage legumes — and is not regarded as notably toxic at dietary levels, which is why the badge is low. The meaningful caution is not classical toxicity but hormonal activity: coumestrol is one of the more potent dietary phytoestrogens, and that estrogenic action is double-edged.

Safety at a Glance

✅ Low / no toxicity

• Low dietary toxicity. Present in common sprouts and legumes at microgram-per-gram levels with a long history of dietary exposure; not phototoxic (a coumestan, not a furanocoumarin).
• Genuine estrogenic activity — cuts both ways. As an ERβ-preferring estrogen agonist it may be supportive in a low-estrogen (postmenopausal) state but unwanted in estrogen-driven conditions; concentrated phytoestrogen supplements are a different exposure from food.
• Hormone-sensitive conditions. Caution is prudent with estrogen-dependent cancers (breast, endometrial) and other hormone-sensitive situations; in-vitro data on breast-cancer cells are mixed — antiproliferative in some assays ^{5Reference 5Al-Thamiree Mezban S · 2023Genistein and coumestrol reduce MCF-7 breast cancer cell viability and inhibit markers of preferential metastasis, bone matrix attachment and tumor-induced osteoclastogenesisView study →} — but an estrogen agonist should not be assumed safe in estrogen-driven disease.
• Reproductive/endocrine signal in animals. Coumestrol is estrogenically active in livestock and rodent reproductive models (the reason it was discovered in forage); reproductive/lactation decisions belong to the source-plant or product page, not to this molecule page.

The hormone-sensitive-cancer question is the one to hold in view. Because coumestrol activates estrogen receptors, a reasonable default is caution in estrogen-dependent cancers even though some in-vitro work reports the opposite: coumestrol (with genistein) reduced MCF-7 breast-cancer-cell viability in an estrogen-receptor-dependent way and suppressed markers of skeletal metastasis ^{5Reference 5Al-Thamiree Mezban S · 2023Genistein and coumestrol reduce MCF-7 breast cancer cell viability and inhibit markers of preferential metastasis, bone matrix attachment and tumor-induced osteoclastogenesisView study →}. Population studies treat dietary phytoestrogens as a group rather than isolating coumestrol ^{9Reference 9Reger MK et al. · 2026ObservationalDietary phytoestrogen intake and risk of receptor-defined breast cancer subtypes: a prospective analysis of the PLCO Cancer Screening Trial cohortView study →}. The prudent reading is that the estrogenic mechanism, not any single assay, sets the caution, and that concentrated supplement-level intake is a different matter from the small amounts in food.

Dosage

There is no established human dose for isolated coumestrol, and it is not sold as a stand-alone supplement. Dietary exposure is small — even sprout-rich diets deliver microgram quantities ^{4Reference 4Ohta T et al. · 2021Effective methods for increasing coumestrol in soybean sproutsView study →} — and far below the doses used in animal research (roughly 5–10 mg/kg, oral or subcutaneous, in ovariectomised-mouse studies) ^{3Reference 3Park S et al. · 2023AnimalProtective effects of coumestrol on metabolic dysfunction and its estrogen receptor-mediated action in ovariectomized miceView study →}. Herbal exposure via alfalfa or clover is indirect and minor, since those plants’ estrogenic effect is dominated by isoflavones rather than coumestrol ^{1Reference 1Reinli K · 1996Phytoestrogen content of foods — a compendium of literature valuesView study →}. Anyone in a hormone-sensitive situation should treat concentrated phytoestrogen products differently from ordinary food. These are research figures, not a personal recommendation.

References

1. Reinli K, Block G (1996). Phytoestrogen content of foods — a compendium of literature values. Nutrition and Cancer. https://pubmed.ncbi.nlm.nih.gov/8875551/
2. Tu Y, et al. (2021). Naturally occurring coumestans from plants, their biological activities and therapeutic effects on human diseases. Pharmacological Research. https://pubmed.ncbi.nlm.nih.gov/33872808/
3. Park S, et al. (2023). Protective effects of coumestrol on metabolic dysfunction and its estrogen receptor-mediated action in ovariectomized mice. Nutrients. https://pubmed.ncbi.nlm.nih.gov/36839308/
4. Ohta T, Uto T, Tanaka H (2021). Effective methods for increasing coumestrol in soybean sprouts. PLoS One. https://pubmed.ncbi.nlm.nih.gov/34793574/
5. Al-Thamiree Mezban S, Fox SW (2023). Genistein and coumestrol reduce MCF-7 breast cancer cell viability and inhibit markers of preferential metastasis, bone matrix attachment and tumor-induced osteoclastogenesis. Archives of Biochemistry and Biophysics. https://pubmed.ncbi.nlm.nih.gov/36967033/
6. Wu XT, Wang B, et al. (2009). Coumestrol promotes proliferation and osteoblastic differentiation in rat bone marrow stromal cells. Journal of Biomedical Materials Research Part B. https://pubmed.ncbi.nlm.nih.gov/19165772/
7. Castro CC, de Souza Pagnussat A, et al. (2022). Coumestrol pre-treatment improves spatial learning and memory deficits following transient cerebral ischemia recruiting hippocampal GluR2 AMPA receptors. Hippocampus. https://pubmed.ncbi.nlm.nih.gov/35347795/
8. Seong SH, et al. (2022). Phytoestrogen coumestrol selectively inhibits monoamine oxidase-A and amyloid β self-aggregation. Nutrients. https://pubmed.ncbi.nlm.nih.gov/36145197/
9. Reger MK, Maxey S, et al. (2026). Dietary phytoestrogen intake and risk of receptor-defined breast cancer subtypes: a prospective analysis of the PLCO Cancer Screening Trial cohort. Cancer Epidemiology, Biomarkers & Prevention. https://pubmed.ncbi.nlm.nih.gov/42377092/
10. Bzdęga W, Żywno H, et al. (2023). Coumestrol as a new substance that may diminish lipid precursors of the inflammation in steatotic primary rat hepatocytes. Biochimie. https://pubmed.ncbi.nlm.nih.gov/36084910/
11. Singla M, et al. (2024). From plants to therapies: exploring the pharmacology of coumestrol for neurological conditions. Current Medicinal Chemistry. https://pubmed.ncbi.nlm.nih.gov/37921179/
12. Bickoff EM, Livingston AL, et al. (1964). Isolation of coumestrol and other phenolics from alfalfa by countercurrent distribution. Journal of Pharmaceutical Sciences. https://pubmed.ncbi.nlm.nih.gov/14255129/

View all 12 references▾